You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDesvenlafaxine
Accession NumberDB06700
TypeSmall Molecule
GroupsApproved
Description

Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin-norepinephrine reuptake inhibitor (SNRI class). Desvenlafaxine may be used to treat major depressive disorder and is being studied for use in the management of vasomotor symptoms in postmenopausal women. It is formulated as an extended release tablet. FDA approved in 2008.

Structure
Thumb
Synonyms
Desvenlafaxine
O-desmethylvenlafaxine
ODV
Pristiq
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Desvenlafaxinetablet, extended release50 mg/1oralRanbaxy Pharmaceuticals Inc.2013-03-05Not applicableUs
Desvenlafaxinetablet, extended release100 mg/1oralSun Pharma Global FZE2014-01-30Not applicableUs
Desvenlafaxinetablet, extended release50 mg/1oralSun Pharma Global FZE2014-01-30Not applicableUs
Desvenlafaxinetablet, extended release100 mg/1oralRanbaxy Pharmaceuticals Inc.2013-03-05Not applicableUs
Desvenlafaxine Extended-releasetablet, extended release50 mg/1oralMacoven Pharmaceuticals2013-07-10Not applicableUs
Desvenlafaxine Extended-releasetablet, extended release100 mg/1oralMacoven Pharmaceuticals2013-07-10Not applicableUs
Khedezla Extended-releasetablet, extended release50 mg/1oralPernix Therapeutics2013-07-10Not applicableUs
Khedezla Extended-releasetablet, extended release100 mg/1oralPar Pharmaceutical Inc.2013-07-10Not applicableUs
Khedezla Extended-releasetablet, extended release50 mg/1oralPar Pharmaceutical Inc.2013-07-10Not applicableUs
Khedezla Extended-releasetablet, extended release100 mg/1oralPernix Therapeutics2013-07-10Not applicableUs
Pristiqtablet (extended-release)100 mgoralPfizer Canada Inc2009-03-06Not applicableCanada
Pristiqtablet (extended-release)50 mgoralPfizer Canada Inc2009-03-05Not applicableCanada
Pristiq Extended Releasetablet, extended release100 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-01-26Not applicableUs
Pristiq Extended-releasetablet, extended release25 mg/1oralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2015-04-01Not applicableUs
Pristiq Extended-releasetablet, extended release100 mg/1oralCardinal Health2008-05-01Not applicableUs
Pristiq Extended-releasetablet, extended release50 mg/1oralCardinal Health2008-05-01Not applicableUs
Pristiq Extended-releasetablet, extended release50 mg/1oralPhysicians Total Care, Inc.2008-05-01Not applicableUs
Pristiq Extended-releasetablet, extended release50 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-04-16Not applicableUs
Pristiq Extended-releasetablet, extended release100 mg/1oralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2008-05-01Not applicableUs
Pristiq Extended-releasetablet, extended release50 mg/1oralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2008-05-01Not applicableUs
Pristiq Extended-release Extended-releasetablet, extended release50 mg/1oralPd Rx Pharmaceuticals, Inc.2008-05-01Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Desvenlafaxinetablet, extended release50 mg/1oralBreckenridge Pharmaceutical, Inc2015-07-13Not applicableUs
Desvenlafaxinetablet, extended release100 mg/1oralBreckenridge Pharmaceutical, Inc2015-07-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Zyven-OD Not Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Desvenlafaxine fumarate
93414-04-1
Thumb
  • InChI Key: SQTJDJZCPOSWSC-WLHGVMLRSA-N
  • Monoisotopic Mass: 379.199487658
  • Average Mass: 379.453
DBSALT001322
Desvenlafaxine fumarate monohydrate
313471-75-9
Thumb
  • InChI Key: YETWCSLOYUZBLK-JITBQSAISA-N
  • Monoisotopic Mass: 397.210052342
  • Average Mass: 397.468
DBSALT001893
Desvenlafaxine succinate
Thumb
  • InChI Key: ORUUBRMVQCKYHB-UHFFFAOYNA-N
  • Monoisotopic Mass: 381.215137729
  • Average Mass: 381.4632
DBSALT000045
Categories
UNIING99554ANW
CAS number93413-62-8
WeightAverage: 263.3752
Monoisotopic: 263.188529049
Chemical FormulaC16H25NO2
InChI KeyInChIKey=KYYIDSXMWOZKMP-UHFFFAOYSA-N
InChI
InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3
IUPAC Name
4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol
SMILES
CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1
Taxonomy
ClassificationNot classified
Pharmacology
IndicationDesvenlafaxine is indicated for the treatment of major depressive disorder in adults.
PharmacodynamicsDesvenlafaxine is a selective serotonin and norepinephrine reuptake inhibitor. It lacks significant activity on muscarinic-cholinergic, H1-histaminergic, or α1-adrenergic receptors in vitro. Desvenlafaxine does not appear to exert activity against calcium, chloride, potassium and sodium ion channels and also lacks monoamine oxidase (MAO) inhibitory activity. It was also shown to lack significant activity again the cardiac potassium channel, hERG, in vitro. Compared to other SNRIs, desvenlafaxine undergoes simple metabolism, has a low risk of drug-drug interactions and does not have to be extensively titrated to reach a therapeutic dose. Some of the limitations of desvenlafaxine include moderate efficacy in the treatment of major depressive disorder, similar safety and tolerability profile to other SNRIs and possible transient discontinuation symptoms upon cessation of therapy.
Mechanism of actionDesvenlafaxine, the major active metabolite of venlafaxine, is a selective serotonin and norepinephrine reuptake inhibitor. The clinical effect of desvenlafaxine is thought to occur via potentiation of serotonin and norepinephrine in the central nervous system. Unlike venlafaxine, desvenlafaxine is thought to have a differential serotonergic and noradrenergic activity profile.
Related Articles
AbsorptionAbsolute bioavailability is approximately 80% and is unaffected by food. Peak plasma concentration is reached in 7.5 hours.
Volume of distribution

3.4 L/kg, distribution into nonvascular compartments

Protein binding~ 30%, protein binding is independent of drug concentration.
Metabolism

The primary route of metabolism is via conjugation mediated by UGT isoforms. Desvenlafaxine also undergoes oxidative N-demethylation via cytochrome P450 3A4 to a minor extent. CYP2D6 is not involved with the metabolism of desvenlafaxine.

SubstrateEnzymesProduct
Desvenlafaxine
N,O-DidesmethylvenlafaxineDetails
Route of eliminationExcreted in the urine. Approximately 45% of the total oral dose is excreted unchanged in urine. Approximately 19% of the total oral dose is excreted as the glucuronide metabolite and < 5% is excreted as the oxidative metabolite, N,O-didesmethylvenlafaxine. Excreted in human milk.
Half lifeThe mean terminal half life is 11.1 hours and may be prolonged in patients with renal and/or moderate to severe hepatic impairment.
ClearanceNot Available
ToxicityThe safety and tolerability of desvenlafaxine is similar to other SNRIs. Common side effects upon initiation or dose increase include increased blood pressure and heart rate, agitation, tremor, sweating, nausea, headache, and sleep disturbances. May cause sexual dysfunction and weight loss in some patients. May cause increases in fasting serum total cholesterol, LDL cholesterol, and triglycerides. Withdrawal effects may occur and thus, the dose of desvenlafaxine should be titrated down prior to discontinuation.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Venlafaxine Metabolism PathwayDrug metabolismSMP00636
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9772
Blood Brain Barrier+0.7722
Caco-2 permeable+0.8404
P-glycoprotein substrateSubstrate0.6918
P-glycoprotein inhibitor INon-inhibitor0.7835
P-glycoprotein inhibitor IIInhibitor0.5921
Renal organic cation transporterNon-inhibitor0.5894
CYP450 2C9 substrateNon-substrate0.7837
CYP450 2D6 substrateSubstrate0.7753
CYP450 3A4 substrateSubstrate0.6997
CYP450 1A2 substrateNon-inhibitor0.6816
CYP450 2C9 inhibitorNon-inhibitor0.757
CYP450 2D6 inhibitorInhibitor0.6334
CYP450 2C19 inhibitorNon-inhibitor0.7811
CYP450 3A4 inhibitorNon-inhibitor0.8646
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8888
Ames testNon AMES toxic0.8084
CarcinogenicityNon-carcinogens0.7648
BiodegradationNot ready biodegradable0.9927
Rat acute toxicity2.4429 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6046
hERG inhibition (predictor II)Inhibitor0.5603
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tablet (extended-release)oral100 mg
Tablet (extended-release)oral50 mg
Tablet, extended releaseoral100 mg/1
Tablet, extended releaseoral25 mg/1
Tablet, extended releaseoral50 mg/1
Prices
Unit descriptionCostUnit
Pristiq 100 mg extended-release tablet4.46USD tablet
Pristiq 50 mg extended-release tablet4.31USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2436668 No2009-05-262022-02-11Canada
US6673838 No2002-03-012022-03-01Us
US8269040 No2007-07-052027-07-05Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySoluble FDA label
logP0.21FDA label
Predicted Properties
PropertyValueSource
Water Solubility1.4 mg/mLALOGPS
logP2.6ALOGPS
logP2.29ChemAxon
logS-2.3ALOGPS
pKa (Strongest Acidic)10.11ChemAxon
pKa (Strongest Basic)8.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area43.7 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity78.54 m3·mol-1ChemAxon
Polarizability30.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Karel Pospisilik, Lambertus Thijs, “Process for making desvenlafaxine.” U.S. Patent US20070299283, issued December 27, 2007.

US20070299283
General References
  1. Ilett KF, Watt F, Hackett LP, Kohan R, Teoh S: Assessment of infant dose through milk in a lactating woman taking amisulpride and desvenlafaxine for treatment-resistant depression. Ther Drug Monit. 2010 Dec;32(6):704-7. doi: 10.1097/FTD.0b013e3181f88f70. [PubMed:20926994 ]
  2. Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008 Dec;8(12):1787-97. doi: 10.1586/14737175.8.12.1787. [PubMed:19086875 ]
  3. Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ: Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2010 Aug;71(8):1088-96. doi: 10.4088/JCP.10m06018blu. [PubMed:20797382 ]
  4. Liebowitz MR, Tourian KA: Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845. doi: 10.4088/PCC.09r00845blu. [PubMed:20944767 ]
  5. Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD: Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther. 2007 Nov;323(2):720-9. Epub 2007 Aug 2. [PubMed:17673606 ]
  6. Montgomery SA, Fava M, Padmanabhan SK, Guico-Pabia CJ, Tourian KA: Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Int Clin Psychopharmacol. 2009 Nov;24(6):296-305. doi: 10.1097/YIC.0b013e32832fbb5a. [PubMed:19779354 ]
  7. Oganesian A, Shilling AD, Young-Sciame R, Tran J, Watanyar A, Azam F, Kao J, Leung L: Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities. Psychopharmacol Bull. 2009;42(2):47-63. [PubMed:19629022 ]
  8. Pae CU, Park MH, Marks DM, Han C, Patkar AA, Masand PS: Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. Curr Opin Investig Drugs. 2009 Jan;10(1):75-90. [PubMed:19127490 ]
  9. Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. [PubMed:19919295 ]
  10. Pae CU: Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother. 2011 Dec;12(18):2923-8. doi: 10.1517/14656566.2011.636033. [PubMed:22098230 ]
  11. Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, Ahmed S, Paul J, Nichols AI: Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol. 2009 Feb;29(1):39-43. doi: 10.1097/JCP.0b013e318192e4c1. [PubMed:19142106 ]
  12. Link [Link]
External Links
ATC CodesN06AX23
AHFS Codes
  • 28:16.04.16
PDB EntriesNot Available
FDA labelDownload (379 KB)
MSDSDownload (86.1 KB)
Interactions
Drug Interactions
Drug
AbciximabDesvenlafaxine may increase the anticoagulant activities of Abciximab.
AcenocoumarolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Acepromazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Acetophenazine.
Acetylsalicylic acidDesvenlafaxine may increase the antiplatelet activities of Acetylsalicylic acid.
AlteplaseDesvenlafaxine may increase the anticoagulant activities of Alteplase.
AmisulprideThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Amisulpride.
AnistreplaseDesvenlafaxine may increase the anticoagulant activities of Anistreplase.
ApixabanThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Apixaban.
AripiprazoleThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Aripiprazole.
BenzquinamideThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Benzquinamide.
CarphenazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Carphenazine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Chlormezanone.
ChlorpromazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Chlorprothixene.
Citric AcidDesvenlafaxine may increase the anticoagulant activities of Citric Acid.
ClozapineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Clozapine.
CollagenaseThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Collagenase.
Dabigatran etexilateDesvenlafaxine may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinDesvenlafaxine may increase the anticoagulant activities of Dalteparin.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Desvenlafaxine.
DasatinibDasatinib may increase the anticoagulant activities of Desvenlafaxine.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Deoxycholic Acid.
DesmopressinDesvenlafaxine may increase the antiplatelet activities of Desmopressin.
DicoumarolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Dicoumarol.
DipivefrinDesvenlafaxine may decrease the antihypertensive activities of Dipivefrin.
DroperidolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Droperidol.
Edetic AcidDesvenlafaxine may increase the anticoagulant activities of Edetic Acid.
EnoxaparinDesvenlafaxine may increase the anticoagulant activities of Enoxaparin.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Desvenlafaxine.
Ethyl biscoumacetateDesvenlafaxine may increase the anticoagulant activities of Ethyl biscoumacetate.
FencamfamineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Fencamfamine.
FlupentixolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Fluspirilene.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desvenlafaxine.
Fondaparinux sodiumDesvenlafaxine may increase the anticoagulant activities of Fondaparinux sodium.
GlucosamineGlucosamine may increase the antiplatelet activities of Desvenlafaxine.
GranisetronGranisetron may increase the serotonergic activities of Desvenlafaxine.
HaloperidolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Haloperidol.
HeparinDesvenlafaxine may increase the anticoagulant activities of Heparin.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Desvenlafaxine.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Ibritumomab.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Desvenlafaxine.
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Desvenlafaxine.
Ioflupane I 123Desvenlafaxine may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
LimaprostLimaprost may increase the antiplatelet activities of Desvenlafaxine.
LinezolidLinezolid may increase the serotonergic activities of Desvenlafaxine.
LoxapineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Loxapine.
MesoridazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Mesoridazine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Methotrimeprazine.
Methylene blueDesvenlafaxine may increase the serotonergic activities of Methylene blue.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Desvenlafaxine.
MolindoneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Molindone.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Desvenlafaxine.
ObinutuzumabThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Obinutuzumab.
OlanzapineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Olanzapine.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Desvenlafaxine.
OndansetronThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Ondansetron.
PaliperidoneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Paliperidone.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Desvenlafaxine.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Desvenlafaxine.
PerphenazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Perphenazine.
PhenelzinePhenelzine may increase the serotonergic activities of Desvenlafaxine.
PhenindioneDesvenlafaxine may increase the anticoagulant activities of Phenindione.
PhenprocoumonDesvenlafaxine may increase the anticoagulant activities of Phenprocoumon.
PimozideThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Pimozide.
PiperacetazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Piperacetazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Promazine.
QuetiapineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Quetiapine.
RemoxiprideThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Reserpine.
ReteplaseDesvenlafaxine may increase the anticoagulant activities of Reteplase.
RidogrelDesvenlafaxine may increase the anticoagulant activities of Ridogrel.
RisperidoneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Risperidone.
RivaroxabanDesvenlafaxine may increase the anticoagulant activities of Rivaroxaban.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Desvenlafaxine.
SertindoleThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Sertindole.
StreptokinaseDesvenlafaxine may increase the anticoagulant activities of Streptokinase.
SulodexideDesvenlafaxine may increase the anticoagulant activities of Sulodexide.
SulpirideThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Sulpiride.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Desvenlafaxine.
TenecteplaseDesvenlafaxine may increase the anticoagulant activities of Tenecteplase.
ThioridazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Thiothixene.
TipranavirTipranavir may increase the antiplatelet activities of Desvenlafaxine.
TositumomabThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Tositumomab.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Desvenlafaxine.
TranylcypromineTranylcypromine may increase the serotonergic activities of Desvenlafaxine.
TreprostinilDesvenlafaxine may increase the anticoagulant activities of Treprostinil.
TrifluoperazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Triflupromazine.
UrokinaseDesvenlafaxine may increase the anticoagulant activities of Urokinase.
Vitamin EVitamin E may increase the antiplatelet activities of Desvenlafaxine.
WarfarinThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Warfarin.
ZiprasidoneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Ziprasidone.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Zuclopenthixol.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH: Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. Epub 2006 May 4. [PubMed:16675639 ]
  2. Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD: Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther. 2007 Nov;323(2):720-9. Epub 2007 Aug 2. [PubMed:17673606 ]
  3. Perry R, Cassagnol M: Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther. 2009 Jun;31 Pt 1:1374-404. doi: 10.1016/j.clinthera.2009.07.012. [PubMed:19698900 ]
  4. Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008 Dec;8(12):1787-97. doi: 10.1586/14737175.8.12.1787. [PubMed:19086875 ]
  5. Liebowitz MR, Tourian KA: Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845. doi: 10.4088/PCC.09r00845blu. [PubMed:20944767 ]
  6. Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. [PubMed:19919295 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH: Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. Epub 2006 May 4. [PubMed:16675639 ]
  2. Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD: Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther. 2007 Nov;323(2):720-9. Epub 2007 Aug 2. [PubMed:17673606 ]
  3. Perry R, Cassagnol M: Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther. 2009 Jun;31 Pt 1:1374-404. doi: 10.1016/j.clinthera.2009.07.012. [PubMed:19698900 ]
  4. Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008 Dec;8(12):1787-97. doi: 10.1586/14737175.8.12.1787. [PubMed:19086875 ]
  5. Liebowitz MR, Tourian KA: Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845. doi: 10.4088/PCC.09r00845blu. [PubMed:20944767 ]
  6. Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. [PubMed:19919295 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Pae CU: Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother. 2011 Dec;12(18):2923-8. doi: 10.1517/14656566.2011.636033. [PubMed:22098230 ]
Comments
comments powered by Disqus
Drug created on May 06, 2010 10:22 / Updated on August 24, 2016 01:51